FAQ

satraplatin

Known as: (OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum, bis-acetatoamminedichlorocyclohexylamine platinum(IV), platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43) 
An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2017
05101519992017

Related topics

Related topics

4 relations

Broader (2)

Antineoplastic AgentsOrganoplatinum Compounds

Narrower (2)

BMS-182751JM 216

Related mentions per year

Related mentions per year

1947-2018
19401960198020002020
satraplatin
Antineoplastic Agents
JM 216
BMS-182751
Organoplatinum Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells.
BACKGROUND The aim of the current study was to identify the antitumor activity of satraplatin in paired cisplatin (CDDP… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The status of platinum anticancer drugs in the clinic and in clinical trials.
Since its approval in 1979 cisplatin has become an important component in chemotherapy regimes for the treatment of ovarian… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2010
2010
Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance
Satraplatin acts as a potent inhibitor of proliferation in castration-resistant prostate cancer, yet the basic and molecular… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial…
PURPOSE This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2007
2007
Preclinical antitumor activity of the oral platinum analog satraplatin
Satraplatin is an orally available platinum analog. The purpose of this study was to better characterize satraplatin’s… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2006
2006
Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin
The goal of this study was to identify molecular determinants of sensitivity and resistance to JM118, the active metabolite of… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2005
2005
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
Satraplatin is a novel oral platinum (IV) complex that shows activity against hormone-refractory prostate cancer (HRPC) in… (More)
Is this relevant?
2005
2005
Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro
Background. Satraplatin is thought to require reduction to a reactive Pt(II) complex (JM118) before exerting chemotherapeutic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2005
2005
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters
Satraplatin is an orally bioavailable platinum analog that has activity in prostate cancer. JM118 is the most abundant species… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
BACKGROUND Satraplatin (JM216; bis-acetatoammine-dichlorocyclohexylamine platinum (IV)) is a platinum (Pt) complex developed in… (More)
Is this relevant?